Efficacy of gefitinib and radiotherapy combination in Indonesian patients with lung adenocarcinoma

1. INDONESIAN NATIONAL COMMITTEE OF CANCER MANAGEMENT (Komite Nasional Penanggulangan Kanker [KPKN]). National Guideline of Lung Cancer Treatment (Panduan Nasional Penanganan Kanker Paru). Ministry of Health, the Republic of Indonesia (Kementrian Kesehatan Republik Indonesia); 2015.p.1-11.Search in Google Scholar

2. JUSUF A., SYARIFUDDIN E., WIBAWANTO A., ICKSAN AG., JUNIARTI J., ENDARDJO S., et al. National Guideline for Diagnosis and Treatment of Non-Small Cell Lung Cancer in Indonesia (Pedoman diagnosis dan penatalaksanaan di Indonesia). The Indonesian Society of Respirology, Jakarta, 2016:1-31.Search in Google Scholar

3. STOECKEL DA., MATUSCHAK GM., Lung Cancer. In: Human Organ System: Respiratory, an integrated approach to disease, McGraw-Hill, New York, 2003:307-318.Search in Google Scholar

4. BRINK DS. Pathology of lung tumors, In: Human Organ System: Respiratory, an integrated approach to disease, McGraw-Hill, New York, 2003:295-305.Search in Google Scholar

5. ISHII AS., KIM Y., SHIOZAWA T., IYAMA S., SATOMI K., KANO J., et al. Stratifin accelerates progression of lung adenocarcinoma at an early stage. Mol Cancer, 2015; 14:142.10.1186/s12943-015-0414-1451868826223682Search in Google Scholar

6. CHANG SC., CHANG CY., SHIH JY., The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. Cancers. 2011; 3(2):2667-78.10.3390/cancers3022667375743624212826Search in Google Scholar

7. RABEN D., Update of EGFR inhibitors and radiation in the management of non-small cell lung cancer, where do we go next? J Thorac Oncol., 2007; 2(8):153-4.10.1097/01.JTO.0000282930.55539.38Search in Google Scholar

8. SATO Y., EBARA T., SUNAGA N., TAKAHASHI T., NAKANO T., Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro. Anticancer Res. 2012; 32(11):4877-4881.Search in Google Scholar

9. IMAI H., SHUKUYA T., TAKAHASHI T, FUJIWARA S, MORI K, ONO A, AKAMATSU H, et al. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor – tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. Anticancer Res. 2013; 33(8):3279-84.Search in Google Scholar

10. YAHYA WS., ANDARINI SL., HUDOYO A., UTOMO AR., Efficacy and toxicities profile of the new epidermal growth factor receptor-tyrosine kinase (Profil efikasi dan toksisitas terapi target baru golongan epidermal growth factor receptor-Tyrosine kinase) [Thesis]. Jakarta: Universitas Indonesia; 2016.Search in Google Scholar

11. CHEN J., FAN M., JIANG G., FU X., XIE L., XU X., et al., Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2010; 78(3):110-11.10.1016/j.ijrobp.2010.07.283Search in Google Scholar

12. XU Y., ZHANG Y., MA S., EGFR inhibitors with concurrent thoracic radiation therapy for locally advances non small cell lung cancer. Lung Cancer. 2011; 73(3):249-55.10.1016/j.lungcan.2011.04.01721641672Search in Google Scholar

13. SHI Y., AU JS., THONGPRASERT S., SRINIVASAN S., TSAI CM., KHOA MT., et al., A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol., 2014 Feb; 9(2):154-62.10.1097/JTO.0000000000000033413203624419411Search in Google Scholar

14. SYAHRUDDIN E., Sindrom vena kava superior. J Respirol Indones., 2009; 29(4):1-9.Search in Google Scholar

15. MOSE S., STABIK C., EBERLEIN K, RAMM U., BOTTCHER HD., BUDISCHEWSKI K., Retrospective analysis of the superior vena cava syndrome in irradiated cancer patients. Anticancer Res., 2006; 26(6C):4933-6.Search in Google Scholar

16. YU HA., SIMA CS., HUANG J., SOLOMON SB., RIMNER A., PAIK P., et al., Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol (2013) 8:346-51.10.1097/JTO.0b013e31827e1f83367329523407558Search in Google Scholar

17. CONFORTI F., CATANIA C., TOFFALORIO F., DUCA M., SPITALERI G., BARBERIS M., et al., EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer, 2013; 81:440-4.10.1016/j.lungcan.2013.05.01923810573Search in Google Scholar

18. LEVY A., BARDET E., LACAS B., PIGNON JP., ADAM J., LACOROIX L., et al., A phase II open label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with in operable stage III non-small cell lung cancer. Oncotarget. 2017; 8(9):15924-33.10.18632/oncotarget.12741536253427764781Search in Google Scholar

19. FAN Y., XU Y., GONG L., FANG L., LU H., QIN J., et al., Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Sci Rep., 2017; 23(7):45193.10.1038/srep45193Search in Google Scholar

20. WAN J., COHEN V., AGULNIK J., FARIA S., PORTELANCE L., OFIARA L., et al., Unexpected high lung toxicity from radiation pneumonitis in a Phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 2009; 75(3): S110.10.1016/j.ijrobp.2009.07.267Search in Google Scholar

21. KRIS MG., NATALE RB., HERBST RS., LYNCH TJ., PRAGER D., BELANI CP., et al., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290(16):2149-58.10.1001/jama.290.16.214914570950Search in Google Scholar